Tyme Technologies (NASDAQ:TYME) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Tyme Technologies (NASDAQ:TYME) from a hold rating to a buy rating in a research note published on Friday morning, Zacks.com reports. They currently have $1.00 price target on the stock.

According to Zacks, “Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body’s immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. “

Separately, HC Wainwright began coverage on Tyme Technologies in a research note on Monday, August 12th. They issued a buy rating on the stock.

Tyme Technologies stock opened at $1.06 on Friday. The firm has a market cap of $111.95 million, a P/E ratio of -3.31 and a beta of 0.40. The business’s fifty day moving average is $1.17 and its two-hundred day moving average is $1.67. Tyme Technologies has a 52 week low of $0.92 and a 52 week high of $4.64.

Tyme Technologies (NASDAQ:TYME) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. As a group, equities analysts forecast that Tyme Technologies will post -0.22 EPS for the current year.

In other Tyme Technologies news, Director David Carberry acquired 30,000 shares of Tyme Technologies stock in a transaction on Friday, June 14th. The shares were bought at an average price of $1.07 per share, with a total value of $32,100.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Michael Demurjian sold 50,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $1.18, for a total value of $59,000.00. The disclosure for this sale can be found here. In the last three months, insiders acquired 60,000 shares of company stock worth $63,450 and sold 140,000 shares worth $156,900. 27.17% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Morgan Stanley lifted its stake in shares of Tyme Technologies by 187.8% during the second quarter. Morgan Stanley now owns 139,579 shares of the company’s stock valued at $170,000 after acquiring an additional 91,081 shares during the period. Paloma Partners Management Co acquired a new position in shares of Tyme Technologies during the second quarter valued at $238,000. Bank of New York Mellon Corp lifted its stake in shares of Tyme Technologies by 5.9% during the second quarter. Bank of New York Mellon Corp now owns 306,199 shares of the company’s stock valued at $374,000 after acquiring an additional 17,173 shares during the period. SG Americas Securities LLC acquired a new position in shares of Tyme Technologies during the first quarter valued at $27,000. Finally, BNP Paribas Arbitrage SA acquired a new position in shares of Tyme Technologies during the first quarter valued at $46,000. 18.57% of the stock is currently owned by institutional investors and hedge funds.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Further Reading: What is quantitative easing?

Get a free copy of the Zacks research report on Tyme Technologies (TYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.